ZFIN ID: ZDB-PUB-101201-41
Ribosomal protein L11 mutation in zebrafish leads to haematopoietic and metabolic defects
Danilova, N., Sakamoto, K.M., and Lin, S.
Date: 2011
Source: British journal of haematology   152(2): 217-228 (Journal)
Registered Authors: Danilova, Nadia, Lin, Shuo
Keywords: haematopoiesis, HSC, p53, Diamond-Blackfan anaemia
MeSH Terms:
  • Anemia, Diamond-Blackfan/drug therapy
  • Anemia, Diamond-Blackfan/genetics*
  • Anemia, Diamond-Blackfan/metabolism
  • Animals
  • Cytoskeleton/metabolism
  • Dexamethasone/pharmacology
  • Dexamethasone/therapeutic use
  • Disease Models, Animal
  • Extracellular Matrix/metabolism
  • Gene Expression Profiling/methods
  • Gene Expression Regulation/drug effects
  • Glucocorticoids/pharmacology
  • Glucocorticoids/therapeutic use
  • Growth Substances/metabolism
  • Hematopoiesis/genetics
  • Mutation*
  • Reverse Transcriptase Polymerase Chain Reaction/methods
  • Ribosomal Proteins/deficiency
  • Ribosomal Proteins/genetics*
  • Tumor Suppressor Protein p53/antagonists & inhibitors
  • Tumor Suppressor Protein p53/genetics
  • Tumor Suppressor Protein p53/metabolism
  • Zebrafish
PubMed: 21114664 Full text @ Br. J. Haematol.
Mutations in ribosomal proteins are associated with a congenital syndrome, Diamond-Blackfan anaemia (DBA), manifested by red blood cell aplasia, developmental abnormalities and increased risk of malignancy. Recent studies suggest the involvement of p53 activation in DBA. However, which pathways are involved and how they contribute to the DBA phenotype remains unknown. Here we show that a zebrafish mutant for the rpl11 gene had defects both in the development of haematopoietic stem cells (HSCs) and maintenance of erythroid cells. The molecular signature of the mutant included upregulation of p53 target genes and global changes in metabolism. The changes in several pathways may affect haematopoiesis including upregulation of pro-apoptotic and cell cycle arrest genes, suppression of glycolysis, downregulation of biosynthesis and dysregulation of cytoskeleton. Each of these pathways has been individually implicated in haematological diseases. Inhibition of p53 partially rescued haematopoiesis in the mutant. Altogether, we propose that the unique phenotype of DBA is a sum of several abnormally regulated molecular pathways, mediated by the p53 protein family and p53-independent, which have synergistic impact on haematological and other cellular pathways affected in DBA. Our results provide new insights into the pathogenesis of DBA and point to the potential avenues for therapeutic intervention.